Caprelsa is indicated for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in adult patients with unresectable locally advanced or metastatic disease. An application for this drug was [...]
Afinitor is currently paid for by provincial drug plans for patients with well-or moderately differentiated neuroendocrine tumours of pancreatic origin (pNET), in patients with unresectable, locally advanced or metastatic disease. [...]
It is with profound sadness that we share the news of the passing of Dr. Suzanne Richter, Medical Oncologist on the NET team at London Health Sciences Centre. This is [...]
CCO to provide Ga-Octreotate to Ontario patients free of charge in Sherbrooke A message from Helena Senta: “At this time, CCO is proceeding with PET scan approval for the [...]
Thank you to all our donors and volunteers! As we start anew into 2017, CNETS Canada would like to acknowledge and thank all our donors and volunteers for their generosity. [...]
Media Release Campaign Shines Spotlight on Rare Cancer on November 10th –World NET Cancer Day Toronto, ON – November 10th, 2016 – Today is World NET Cancer Day. To raise [...]
Media Advisory “LET’S TALK ABOUT NETs” Campaign Shines Spotlight on Rare Cancer Toronto, ON – October 27, 2016 – Between 12,000 to 15,000 Canadians are estimated to have a rare [...]
On October 2, 2016, CNETS Canada held a Toronto Patient Education Day entitled PRRT Clinical Trial Update – PMH Site, with presentations by Dr. Rebecca Wong and Dr. Shereen Ezzat. [...]
Clinical benefit demonstrated with everolimus and pasireotide LAR alone or in combination in the first randomised, prospective study entirely dedicated to advanced lung and thymic carcinoids. In patients with advanced [...]
CNETS Canada is looking to gain insight into the Canadian neuroendocrine (NET) cancer patient experience with Gallium 68 scans to date. This information will assist us in developing next steps [...]